Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on November 29, 2022, Navidea and its majority-owned subsidiary Macrophage Therapeutics, Inc. filed an appeal of the judgment by the District Court of Harris County, Texas in Case No. 2018-24442-151; Capital Royalty Partners II, L.P. et al. v. Navidea Biopharmaceuticals, Inc. and Macrophage Therapeutics, Inc., with the 14th Court of Appeals of Texas for review by the appellate court.
Bitcoin, Ethereum, Dogecoin Fail To Impress, Cardano Bucks The Trend; This Analyst Is Warning Of A Massive 2022 Crash That ‘Will Flush Everyone Out’
Bitcoin (CRYPTO: BTC) and Ethereum (CRYPTO: ETH) traded in red on Monday evening as the global cryptocurrency market cap decreased 0.5% to $2.4 trillion.
